Valeo Financial Advisors LLC lowered its position in GSK plc (NYSE:GSK – Free Report) by 31.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and ...
UK pharma major GSK late Friday announced that the US Food and Drug Administration (FDA) has approved Penmenvy (meningococcal ...
The U.S. Food and Drug Administration approved British drugmaker GSK's combination vaccine to protect against meningococcal ...
GSK plc (LON:GSK – Get Free Report) insider Emma Walmsley sold 120,653 shares of the firm’s stock in a transaction on Monday, ...
Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...
Q4 2024Management ViewCEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over ...
Chief executive Emma Walmsley said ministers must work with the sector to boost investment amid growing concerns about doing ...
Chief Commercial Officer Luke Miels explained that while near-term challenges persist, the partnership with Zhifei positions GSK for long-term success. Richard Parkes, BNPP Exane: Inquired about ...
Orchard Therapeutics has tasked Robin Kenselaar with accelerating growth of Lenmeldy, the world’s most expensive drug, ...
Here are today's Five Things You Need to Know, plus a look at numbers from the big game and my favorite commercial. Good morning, Boston. Did you stay up for the whole game last night? (I didn’t.) ...
The encouraging results were further fueled by GSK’s strong optimism around its drug pipeline and future commercial launches, based on which management hiked its sales outlook for 2031.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback